Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Augusta University
European Organisation for Research and Treatment of Cancer - EORTC
The University of Texas Health Science Center at San Antonio
Duke University
Philogen S.p.A.
Istari Oncology, Inc.
CNS Pharmaceuticals, Inc.
Philogen S.p.A.
Actuate Therapeutics Inc.
Children's Oncology Group
Istituto Oncologico Veneto IRCCS
AbbVie
M.D. Anderson Cancer Center
Universitair Ziekenhuis Brussel
Hoffmann-La Roche
Alliance for Clinical Trials in Oncology
Isarna Therapeutics GmbH
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
Incheon St.Mary's Hospital
M.D. Anderson Cancer Center